secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001193125-25-315918
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evommune reports Q3 2025 net loss $12.5M; IPO raised $172.5M, three Phase 2 readouts due in 2026
--------------------------------------------------------------------------------

- Completed IPO in Nov 2025 of 10.78M shares at $16.00, raising $172.5M gross proceeds.
- Three Phase 2 data readouts expected in 2026: EVO756 CSU (1H26), EVO756 AD (2H26), EVO301 AD (1H26).
- Q3 2025 revenue $10.0M from Maruho collaboration; zero in prior-year quarter.
- Net loss improved to $12.5M vs $15.9M YoY; cash and investments $76.0M as of Sep 30, 2025.
- R&D expenses increased to $19.6M from $13.3M YoY, reflecting pipeline advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/0001193125-25-315918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/evmn-20251211.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-315918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer